Previous 10 | Next 10 |
-Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic ® and Triferic ® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis an...
WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for pa...
WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received fee...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! Source: f11photo/Shutterstock.com Earnings reports, study results, a rever...
WIXOM, Mich., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the publication of r...
Rockwell Medical, Inc. (RMTI) Q3 2021 Earnings Conference Call November 15, 2021, 04:00 PM ET Company Participants Jason Finkelstein - SVP, Argot Partners, IR Russell Ellison - President & CEO Russell Skibsted - EVP, CFO & Chief Business Officer Marc Hoffman - Chief Medical Officer Co...
Rockwell Medical (NASDAQ:RMTI): Q3 GAAP EPS of -$0.08 misses by $0.01. Revenue of $16M (+4.7% Y/Y) misses by $2.18M. Press Release For further details see: Rockwell Medical EPS misses by $0.01, misses on revenue
- Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients recei...
Rockwell Medical (NASDAQ:RMTI) is scheduled to announce Q3 earnings results on Monday, November 15th, after market close. The consensus EPS Estimate is -$0.07 (+30.0% Y/Y) and the consensus Revenue Estimate is $18.18M (+19.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revi...
News, Short Squeeze, Breakout and More Instantly...
Rockwell Medical Inc. Company Name:
RMTI Stock Symbol:
NASDAQ Market:
Rockwell Medical Inc. Website:
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the ...